Micron Makes the $1 Trillion Club a Little More Crowded

Micron crossed $1 trillion in market value as AI-driven high-bandwidth memory demand and long-term contracts through 2029 support a stronger earnings outlook, though the cyclical risks remain. Eli Lilly reported encouraging early Phase 1B data for VERVE-102, with LDL cholesterol reduced by up to 62% after one infusion, while also deploying up to $4 billion across three vaccine acquisitions. Zscaler beat Q3 expectations but fell 30% after cutting full-year free cash flow margin guidance to 23% from 26.8% on AI capex spending and softer guidance.

Analysis

Micron’s rerating is less about a one-quarter inflection and more about the market re-pricing memory from a cyclical input into a capacity-constrained strategic component. The second-order winner is the AI stack above it: if HBM remains pinned by long-dated contracts and multi-year fab lead times, hyperscalers and accelerator vendors get forced into higher bill-of-materials costs, which should widen the gap between vendors with pricing power and everyone else. The risk is not demand collapse first; it is customer design substitution and workload optimization over 12-24 months, where architects start reducing memory intensity per model or shifting inference economics to lower-spec tiers.

The bigger contrarian point on Micron is that peak valuation danger can appear while fundamentals still look pristine. When supply is locked and earnings estimates are still catching up, the stock can stay “cheap” on trailing metrics longer than bears expect, but the P/E can compress violently once the market stops extrapolating contract scarcity into perpetual scarcity. A practical trigger to fade is not the first hint of slowing orders, but evidence that new capacity from multiple vendors or customer inventory normalization begins to narrow the demand gap before 2028.

Eli Lilly is quietly turning excess cash flow into an option portfolio on future revenue streams, which is exactly what a quality pharma compounder should do late in a growth cycle. The durable edge here is not any single pipeline asset; it is the ability to fund multiple shots on goal while competitors remain capital constrained. The market may be underestimating how much this de-risks the post-GLP-1 transition, but the real watch item is whether these acquisitions translate into internally developed platforms or remain financial optionality with low near-term EPS impact.

Key Decisions for Investors

• MU: Stay long, but trim into strength over the next 2-6 weeks rather than chasing; upside can extend on contract scarcity, but the asymmetry worsens once the market starts pricing 2027-2028 supply normalization.
• MU vs. ZS pair: Long MU / short ZS for 1-3 months as a relative-value expression of capex beneficiaries versus capex consumers; thesis works if AI infrastructure pricing pressure keeps hitting software margins more than memory pricing.
• ZS: Avoid adding immediately after the drawdown; wait for one more quarter of confirmation on free cash flow margin before stepping in. If FCF margin stabilizes, a rebound to pre-earnings valuation is plausible over 3-6 months.
• LLY: Maintain core long exposure and consider using call spreads into any biotech pullback; the cash-rich M&A strategy reduces long-cycle earnings risk, so upside is more likely to come from multiple expansion than immediate EPS beats.
• NVDA/INTC suppliers: Monitor for follow-on upside in the memory and HBM supply chain, but prefer the component bottlenecks over the platform names for the next 6-12 months because pricing power is currently concentrated upstream.